{"id":775720,"date":"2023-08-04T19:11:53","date_gmt":"2023-08-04T23:11:53","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-to-host-extraordinary-general-meeting-of-shareholders-on-september-1st-2023\/"},"modified":"2023-08-04T19:11:53","modified_gmt":"2023-08-04T23:11:53","slug":"nanobiotix-to-host-extraordinary-general-meeting-of-shareholders-on-september-1st-2023","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-to-host-extraordinary-general-meeting-of-shareholders-on-september-1st-2023\/","title":{"rendered":"NANOBIOTIX to Host Extraordinary General Meeting of Shareholders on September 1st, 2023"},"content":{"rendered":"
\n

PARIS and CAMBRIDGE, Mass., Aug. 04, 2023 (GLOBE NEWSWIRE) — NANOBIOTIX<\/a>\u00a0(Euronext: NANO \u2013\u2013 NASDAQ: NBTX \u2013 the \u2018\u2018Company\u2019\u2019), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, <\/strong>today announced that the Company will host an Extraordinary General Meeting of Shareholders (\u201cEGM\u201d) on September 1st<\/sup>, 2023 at 02:00 pm CEST at its headquarters.<\/p>\n

In order to implement the set of agreements disclosed in the press release dated July 10, 2023, Nanobiotix will host a shareholders meeting on September 1st<\/sup>, 2023 for submitting to the approval of its shareholders the issuance of a number maximum of 959,638\u00a0shares to be subscribed by Johnson & Johnson Innovation \u2013 JJDC, Inc. in consideration of an initial tranche equal to $5 million resulting in a capital increase for a total nominal amount of \u20ac28,789.14.<\/p>\n

Copy of the notice of meeting of this EGM issued in the Bulletin des Annonces L\u00e9gales Obligatoires (BALO\/Mandatory Legal Notice Bulletin) includes text of the draft resolutions and outlines the terms of participation as well as instructions to vote in this Meeting and is available on the Company\u2019s website.<\/p>\n

\n About NANOBIOTIX <\/strong>
\n
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The company\u2019s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.<\/p>\n

Incorporated in 2003, Nanobiotix is headquartered in Paris, France. The company also has subsidiaries in Cambridge, Massachusetts (United States), France, Spain, and Germany. Nanobiotix has been listed on Euronext: Paris since 2012 and on the Nasdaq Global Select Market in New York City since 2020.<\/p>\n

Nanobiotix is the owner of more than 20 patent families associated with three nanotechnology platforms featuring applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system. The company’s resources are primarily devoted to the development of its lead product candidate\u2013NBTXR3\u2014which is the product of its proprietary oncology platform and has already achieved market authorization in Europe for the treatment of patients with soft tissue sarcoma under the brand name Hensify\u00ae.<\/p>\n

For more information about Nanobiotix, visit us at www.nanobiotix.com<\/a> or follow us on LinkedIn<\/a> and Twitter<\/a>.<\/p>\n

\n Contacts<\/strong>\n <\/p>\n\n\n\n\n\n
\n Nanobiotix<\/em>\n <\/td>\n<\/tr>\n
\n Communications Department<\/strong>
\n
\n Brandon Owens<\/em>
\n
\n VP, Communications<\/em>
\n
+1 (617) 852-4835
contact@nanobiotix.com<\/a>\u00a0<\/td>\n		\n Investor Relations Department<\/strong>
\n
\n Craig West<\/em>
\n
\n SVP, Investor Relations<\/em>
\n
+1 (617) 583-0211
investors@nanobiotix.com<\/a>\u00a0<\/td>\n<\/tr>\n
\n Media Relations<\/em>\n <\/td>\n<\/tr>\n
\n
FR \u2013 Ulysse Communication<\/strong>
Pierre-Louis Germain
+ 33 (0) 6 64 79 97 51
plgermain@ulysse-communication.com<\/a><\/p>\n<\/td>\n		Global \u2013 LifeSci Advisors<\/strong>
Ligia Vela-Reid
+44 (0) 7413825310
Lvela-reid@lifesciadvisors.com<\/a><\/u><\/td>\n<\/tr>\n<\/table>\n

\u00a0<\/p>\n

\n Attachment<\/strong>\n <\/p>\n